MedTrace Logo

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

NCT04466618 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2023-12-26

Study results available
· View outcomes & findings →

Summary

GLP-1 is a hormone made by the body that promotes the production of insulin in response to GLP-1 is produced within the islets expressing prohormone convertase 1/3eating. However, there is increasing evidence that this hormone might help support the body's ability to produce insulin when diabetes develops. The purpose of this study is to determine the effect of endogenous GLP-1 secretion on insulin secretion in people with and without type 2 diabetes.

Conditions

Interventions

BIOLOGICAL

Saline

Saline infused during the study

BIOLOGICAL

Exendin-9,39

Exendin-9,39 infused during the study

BIOLOGICAL

Saline + Intralipid/Heparin

Saline infused during acute insulin resistance

BIOLOGICAL

Exendin-9,39 + Intralipid/Heparin

Exendin-9,39 infused during acute insulin resistance

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Adrian Vella

    lead OTHER

Principal Investigators

  • Adrian Vella · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-15
Primary Completion
2022-12-15
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04466618 on ClinicalTrials.gov